RSS Feeds
Cimetidine and Acute Intermittent Porphyria
- Jose Halabe Cherem, MD;
- Jose Malagon, MD; and
- Haiko Nellen, MD
- From Hospital de Especialidades, Centro Médico Nacional Siglio XXI IMSS, 06720 Mexico D.F.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Management of acute porphyric crisis involves withdrawal of offending drugs, treatment of symptoms with appropriate medications, and attempts to reverse factors that increase aminolevulinic acid synthetase activity. Hematin, the standard therapy for porphyria, is not always immediately available. Cimetidine may have a role in the treatment of acute intermittent porphyria by inhibiting heme oxidase activity, decreasing …
This 100-word excerpt has been provided in the absence of an abstract.
